Quality of life and radiotherapy in brain metastasis patients  by Fernandez, Gonçalo et al.
OQ
G
M
R
a
A
R
R
2
A
K
B
Q
R
W
1
B
r
a
d
1
hreports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 281–287
Available  online  at  www.sciencedirect.com
jou rn al h om epa ge: ht tp : / /www.e lsev ier .com/ locate / rpor
riginal research article
uality  of  life and  radiotherapy  in brain  metastasis  patients
onc¸alo Fernandez ∗, Rute Pocinho, Catarina Travancinha, Eduardo Netto,
argarida Roldão
adiotherapy Department at Instituto Português de Oncologia de Lisboa – Francisco Gentil, Portugal
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 19 November 2011
eceived in revised form
 August 2012
ccepted 10 August 2012
eywords:
rain metastases
uality-of-life
adiotherapy
hole brain radiotherapy
a  b  s  t  r  a  c  t
Aim: The primary objective of this study was to assess whether there was an improvement
in  QoL for patients with brain metastases after radiotherapy treatments.
Background: Assessment of quality of life (QoL) in brain metastasis patients has become
increasingly recognized as an important outcome.
Materials and methods: Patients treated for brain metastasis in our department during 2010
were included in our prospective study. QoL assessments were conducted at baseline, 1
month, and 3 months after completion of whole-brain radiotherapy (WBRT). Wilcoxon test
for  multiple comparisons was calculated to detect signiﬁcant differences in global QoL
scores.
Results: Thirty-nine patients with brain metastases completed the EORTC QLQ-C30/BN-20
questionnaire independently. Median age was 59.9 years (from 37 to 81 years). Our results
report differences between the baseline and 3 months in worsening of a global health status
(p  = 0.034) and cognitive function (p = 0.004), as well as drowsiness (p = 0.001), appetite loss
(p  = 0.031) and hair loss (p = 0.005). There is a tendency for deterioration of physical func-
tion  (p = 0.004), communication deﬁcit (p = 0.012), and weakness of legs (p = 0.024), between
the  baseline and 1 month evaluation. There was no difference in a global cognitive status
between different evaluations. Median survival time was 3 months (CI 95% 1.85; 4.15).
Conclusions: Our ﬁndings indicate a small deterioration for a global QoL status, and large
deterioration for cognitive function after radiation treatments, as well as worsening of brainmetastasis related symptom items. Further research is necessary to reﬁne treatment selec-
tion  for patients with brain metastases, since it may at least contribute to the stabilization
of  their QoL status.
©  2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
especially for breast, lung, and kidney, as a result of more
efﬁcient regimens.4 The results of recent studies show that.  Background
rain metastases represent one of the most common and
efractory malignancies worldwide with a rising incidence in
ll countries.1 Approximately 10–30% of patients with cancer
evelop brain metastases during the course of their illness
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as an indicator of disease’s progression.2,3 An increasing
trend toward prolonged patient survival has been reported,a Basto, 1099-023 Lisbon, Portugal. Tel.: +351 912124841.
early identiﬁcation and aggressive treatment can often ame-
liorate symptoms and increase both the survival and the
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Table 1 – Patient characteristics at baseline (WBRT – whole brain radiotherapy; RPA – recursive partitioning analysis; GPA
– graded prognostic assessment).
Number of
patients (n)
Percentage (%)
Median age (years) 59.9 (37–81)
Primary tumor Lung 14 36.0
Breast 16 41.0
Melanoma 2 5.1
Colorectal cancer 2 5.1
Others 5 12.8
RPA classiﬁcation I 15 38.5
II 5 12.8
III  19 48.7
GPA classiﬁcation 0–1 20 51.3
1.5–2.5 16 41.0
3 3 7.7
3.5–4 0 0
Karnofsky 90–100 11 28.2
performance status 89–71 9 23.1
<70 19 48.7
Number of lesions 1 12 30.8
2–3 11 28.2
>3 16 41.0
Fractionation of WBRT 30 Gy/10Fr 37 94.9
20 Gy/5Fr 2 5.1
Initial steroid dose (dexamethasone) 4 mg 21 56.8
5–15 mg 8 21.6
>16 mg 8 21.6
sive Extra-cranial Not progres
Tumor status Progressive 
quality of life (QoL). During the past two decades, techni-
cal advances have been made in diagnosis and treatment of
brain metastases. The cornerstones of treatment are surgery,
whole brain radiotherapy (WBRT), and radiosurgery (RS).5–7
Since the majority of patients present with multiple lesions
or widespread metastatic disease, WBRT  is a standard treat-
ment to provide symptomatic relief, to allow for tapering of
corticosteroid’s dose, and possibly improve survival. Although
many  trials have shown that WBRT  can reduce neurologi-
cal symptoms, the median survival following the diagnosis
of brain metastasis is generally only 2–4 months.8 With the
evolution of treatment techniques (RS and improved surgical
interventions), there is a growing interest in stratifying these
patients into those that should be treated aggressively due to a
potential for longer survival, and those who should be treated
with simple WBRT  because of their poor survival potential.9
Radiation Therapy Oncology Group (RTOG) database of clinical
trials has developed the two most rigorous prognostic indices,
the recursive partitioning analysis (RPA) and the graded pro-
gnostic assessment (GPA). RPA has been the gold standard for
more  than a decade, whereas GPA is its recent reﬁnement.10–12
It is worth noting that most patients treated for brain
metastases die of extracranial disease.13 This is an important
consideration because, although most studies have used over-
all survival as the main endpoint, survival is probably not the
best parameter to measure the efﬁcacy of the existing ther-
apeutic modalities.14 In this context, the assessment of QoL
and neurocognitive function in patients with brain metastases
has become increasingly recognized as an important addition
to traditional outcome measures, such as length of survival
and time to disease progression. The use of QoL outcomes13 33.3
26 66.6
could provide prognostic information, allowing identiﬁcation
of patients who will beneﬁt from a speciﬁc intervention,
preventing overtreatment of patients, or facilitating decision
making for poorer prognosis patients less likely to beneﬁt
from WBRT.15,16 Therefore, it is imperative for clinicians to
be familiarized with QoL tools and utilities, since palliative
therapy courses should aim to improve or at least stabilize
QoL.
2. Aim
Few studies have focused on QoL and cognitive assessments
as primary outcome. The primary objective of this study was
to assess QoL for patients with brain metastases measured 1
and 3 months after radiation therapy treatments. Secondary
objectives were to evaluate disease survival and cognitive
impairment after treatment.
3.  Materials  and  methods
All patients with diagnosed brain metastases referred to
receive WBRT  during the year 2010 in the Radiotherapy Depart-
ment at Instituto Português de Oncologia de Lisboa – Francisco Gentil
were included in our prospective study. Ethics approval was
obtained from the hospital research ethics board. Comput-
erized tomography (CT) and/or magnetic resonance imaging
(MRI) scanning of the brain was mandatory. Patients with
language barrier or signiﬁcant cognitive impairment were
excluded. Suitable patients were considered for RS at an afﬁl-
iated hospital. The dose of 30 Gy in ten fractions is a standard
radiotherapy 1 7 ( 2 0 1 2 ) 281–287 283
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BRT  regimen at our center for patients with brain metas-
ases. Proxies were not used because they have been shown
o have a poor concordance with self-reports in the setting of
rain metastases.
All patients were prescribed dexamethasone at varying
oses during radiotherapy and were given a tapering sched-
le after completion of WBRT.  Outcomes of patients were
easured up to September 2011. All patients were asked to
omplete the European Organization of Radiotherapy treat-
ents QoL questionnaire (EORTC QLC 30/BN20) independently
t different times of evaluation.17 QoL assessments were con-
ucted at baseline (before ﬁrst day of WBRT), 1 month, and
 months after completion of WBRT.  Overall survival (OS) was
alculated using Kaplan–Meier estimators and Mantel–Cox log
ank test was used to detect signiﬁcant differences between
ubgroups. QoL results are presented as mean scores and
ere compared between time points and between subgroups
f patients using the Wilcoxon test to detect signiﬁcant dif-
erences in global QoL scores. Neurocognitive function was
ssessed by the Mini Mental State Examination (MMSE) at
ach QoL evaluation. Patients were grouped according to the
PA and GPA classiﬁcation. QLQ-C30 and BN20 instruments
ave been developed by the EORTC Quality of Life Study
roup for measuring the QoL of cancer patients in clini-
al trials.17 The QLQC30 contains 30 items and covers the
omains of physical, role, emotional, cognitive, and social
unction, as well as a global health status and several symp-
oms. The BN20 questionnaire is a brain-speciﬁc module to
e used in conjunction with QLQ-C30 and contains 20 items,
rouped into four domains (future uncertainty, visual disor-
er, motor dysfunction and communication deﬁcit) as well
s seven single items (headaches, seizures, drowsiness, hair
oss, itchy skin, weakness of legs, bladder control). Ques-
ionnaire data was processed according to the procedures
utlined in the EORTC QLQ-C30 scoring manual.18 Taking
nto account language validation and the more  extended
xperience in the EORTC QLQ-C30/BN20, we chose this ques-
ionnaire as the best option to evaluate our patients’ QoL
utcomes.
.  Results
rom January to December 2010, 46 patients with brain metas-
ases were referred for consideration of WBRT.  Of these, 39
atients were included in the study. Seven patients were
xcluded because of language barrier, cognitive impairment
mpeding ability to participate, and a very low performance
tatus.
No patient declined participation. Sixty-two percent of
atients were female, and 38% were male, with 59.9 years
edian age (range, 37–81). Median baseline KPS score was 60
range, 50–100). Patient demographics are shown in Table 1.
he most common primary cancers were breast (41%) and
ung (35.9%). Median time from primary diagnosis until brain
etastasis diagnosis was 6.2 months. Seven patients wereubmitted to previous surgery with brain lesion resection
efore WBRT.  Thirty one percent of patients presented with
 single brain metastasis, 15.4% had two lesions, and 53.8%
ad three or more  lesions. Median diameter of the largest
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Fig. 1 – Overall survival outcomes according to recursive
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Fig. 2 – Overall survival outcomes according to graded
partitioning analysis (RPA).
lesion was 16.9 mm,  the second largest was 9.1 mm,  and third
one, 6.8 mm.  Twenty percent of patients were taking anti-
seizure medication. Forty-ﬁve percent of patients were taking
dexamethasone at the time of initial consultation, with 21.6%
having been prescribed 16 mg  per day. All patients were pre-
scribed dexamethasone at varying doses during radiotherapy.
The median time between brain metastasis diagnoses and ini-
tial radiation therapy/surgery was 2 weeks, with a range from
6 days to 18 weeks. The most commonly used radiotherapy
dose fractionation schedule was 30 Gy in ten fractions, with a
median treatment duration of 13 days. Out of the 39 patients,
71.8% were treated with isolated WBRT,  17.9% had WBRT  after
metastasectomy and 10% were treated with RC after WBRT.
All patients completed the EORTC QLQ-C30 and BN20 instru-
ments at baseline, 24 (61.5%) at 1 month, and 19 (48.7%) at 3
months.
In QoL assessment, differences were observed from base-
line evaluation to 1 month after treatment evaluation in
worsening of global health status (p = 0.009), physical func-
tion (p = 0.004), cognitive function (p = 0.004), communication
deﬁcit (p = 0.012), drowsiness (p < 0.001), hair loss (p = 0.001),
and weakness of legs (p = 0.024). Between 1 and 3 months after
treatment, there was no statistical difference detected in QoL
assessment. Between baseline and 3 months after completion
of radiation treatments, differences were observed in deterio-
ration of global health status (p = 0.034), cognitive functioning
(p = 0.004), appetite loss (p = 0.031), drowsiness (p = 0.001), and
hair loss (p = 0.005). All comparisons were made using the
Wilcoxon test (Table 2 and Fig. 1). There were no differences
in global cognitive status (MMSE) between baseline (median
24.9) and 3 months after radiation treatment (median 24.1).
Twenty seven (69.2%) death events occurred during the study.
The median survival time of the entire cohort is 3 months (CI
95% 1.85; 4.15).
Fig. 1 shows survival curves of patients divided by the
RPA class. Almost half of the patients were classiﬁed as
class III (19 patients), 12.8% were class II (5 patients), and
38.5% were class I (15 patients). During follow-up, 17 patients
(89.5%) of the 19 patients classiﬁed in RPA III died as did all
patients classiﬁed in RPA II. In RPA class I, death occurredprognostic assessment (GPA).
in 5 patients (35%). Median OS on RPA II and RPA III was
3 (CI95% 1.83; 4.17) and 2 months (CI 1.85; 4.15), respec-
tively. Since the death rate in RPA I was lower than 50%,
we could not determine a median OS in this sub-group of
patients.
Fig. 2 shows survival curves of patients divided by the
GPA class. Seventeen (89.5%) of the 19 patients classiﬁed in
GPA 1 and 9 (60%) of the 15 patients in GPA 2 died dur-
ing follow up. All 3 patients classiﬁed in GPA 3 were alive
during follow-up. Median OS for GPA 1 and GPA 2 was 2
months (CI95%: 1.08; 2.92) and 5 months (IC95%: 1.55; 8.45),
respectively.
5. Discussion
Recently, QoL has become an increasingly important outcome
in cancer trials. Several trials on brain metastasis have been
published that included an evaluation of study population’s
QoL.13,19–23 Although there are numerous QoL questionnaires,
no standard questionnaire is currently used to access QoL in
patients with brain metastases. Nowadays, the use of these
different questionnaires does not allow for a comparison of
QoL trials. A standard tool would be beneﬁcial for comparisons
across trials and allowing meta-analysis.
Literature review showed that certain parameters of QoL
deteriorate after WBRT.14,24,25 These ﬁndings have led authors
to question whether patients with poor prognosis beneﬁt
from radiotherapy in terms of effect on QoL and symp-
tom experience. For patients with better prognosis, some
studies have shown certain parameters of QoL signiﬁcantly
improved after WBRT.15,16 Yaneva and Semerdijeva20, used
the EORTC QLQC30 in a patients population with KPS > 70
who underwent WBRT,  with signiﬁcant improvements in
functional indicators, symptoms, and health-related QoL.
These results differ from the ﬁndings of Gerrad et al.14,
who also used the QLQ-C30 questionnaire. Their popula-
tion had KPS < 70, more  than 60 years, or a primary site
other than the breast. Our results reported p values statisti-
cally signiﬁcant between baseline and 3 months for a small
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eterioration of global health status and large deterioration
f cognitive function, as well as worsening of drowsiness,
ppetite loss and hair loss. There was a tendency for dete-
ioration of physical function and weakness of legs (Table 2).
n all other QoL domains, no statistically signiﬁcant changes
ere obtained. Although a considerable improvement in QoL
as not evident, WBRT  may have contributed to the stabi-
ization of the QoL status. It is of note that no correlation
as observed between steroid intake and the worsening of
ppetite loss item, since all patients were with corticosteroid
ntake of at least 4 mg/day. Reporting of steroid use in assess-
ng brain metastasis patients was non-uniform. There is not
ufﬁcient literature concerning additional beneﬁts of steroid
herapy with WBRT;  nevertheless, corticosteroids are recom-
ended to provide temporary relief of symptoms related to
ncreased intracranial pressure and edema secondary to brain
etastasis.26,27
Steinmann et al.23 prospectively studied QoL of 46 patients
ith previously untreated brain metastases at start of treat-
ent and 3 months after treatment. QoL deteriorated in most
omains, signiﬁcantly in drowsiness, hair loss and weakness
f legs. The scores for headaches and seizures were slightly
etter after 3 months. Assessment by proxies also suggested
he worsening of QoL. Initial QoL at baseline was better in
hose alive than in those deceased at 3 months evaluation,
igniﬁcantly for the physical function and symptom scales of
atigue and pain, motor dysfunction, communication deﬁcit
nd weakness of legs.
In our study, almost half of the patients (19 patients) had
oor performance status, reﬂected in the low median survival
f 3 months for the total population of patients. This is con-
istent with the ﬁndings of retrospective studies from other
enters.9,10,13,14,28 This low median survival emphasizes once
ore the need to reﬁne treatment selection for patients with
rain metastases.
It  is well known that prognostic tools are useful to guide tai-
ored strategies for cancer. Many  factors, including but not lim-
ted to performance status (KPS), age, extracranial disease and
rimary tumor status, have been identiﬁed as prognostically
elevant in brain metastasis patients outcome. Other factors,
uch as number, size, location of intracranial lesions, histol-
gy of the primary malignancy and interval between primary
umor diagnosis and detection of brain disease have been less
onsidered.29 Niemec et al.30 also reported that such factors
s adenocarcinoma histology and female sex were prevalent
n long-term survivors of brain metastases from lung cancer.
PA was the ﬁrst and most commonly used scoring system to
lassify brain metastasis survivorship categories,10 although
ther systems have also been developed. The GPA score, beside
ncluding age, KPS, and extracranial metastasis, also assigned
he number of brain metastases as a scoring parameter. Some
uthors described this particular scoring system as the most
bjective, quantitative and easiest to be used.31,32 Villa et al.33
ecided to prospectively analyze the GPA index score, and
ompared it to other published prognostic indices, including
PA, to assess the prediction performances of those prognosti-
ation systems. Their data did not suggest a greater prognostic
ower of one scoring system over another, and stated that GPA
lass may be more  difﬁcult to use for daily prognostication of
rain metastasis patients. Our results suggest that both RPAtherapy 1 7 ( 2 0 1 2 ) 281–287 285
class 3 patients and GPA 0–1 do poorly, with a median survival
of 2 months in both groups. This data is consistent with other
studies.14,24,25 In our experience, both GPA and RPA were a use-
ful predictive models, nevertheless, as the authors explained,
caution should be exercised by treating physicians to use these
prognostic models and to comprehensively integrate other
health, familial and socioeconomical related parameters to
this very heterogeneous population of patients with brain
metastases.
Neurocognitive function is also an important concern for
brain metastasis patients. In our study, we  used MMSE  to
assess cognitive impairment, and to validate the response
to our questionnaires. There was no statistically signiﬁcant
difference between sets in MMSE score results. Although
the MMSE is the most frequently used measure of the neu-
rocognitive function in the studies, it is less sensitive to
mild neurocognitive impairment and may not identify sub-
tle improvements.34,35 In addition, the MMSE has not been
as thoroughly evaluated in patients with brain metastases
compared with patients with primary brain tumors. Li et al.36
concluded in their study with patients who had been treated
with radiosensitizer (gadolinium) and WBRT  that there is a
correlation between the neuro-cognitive function and QoL,
and that efforts to prevent the worsening of neurocognitive
function could help maintain QoL.
We do recognize that our number of patients is quite lim-
ited, especially those who completed all tree questionnaires
(19 patients). Speciﬁc effects in subgroups of patients (as in
RPA/GPA group, or MMSE evaluation) may only be detectable
in a much larger study. During our study, we  noticed that
QLQ-C30/BN-20 were time consuming, taking sometimes over
20 min  to complete, which was an issue of considerable impor-
tance especially on severely ill patients with low performance
status. Steinmann et al.23 validated a shortened version of
QLQ-C30 in their study. QLQC15-PAL is used in a palliative-care
setting; containing only 15 items which can be completed in a
much shorter time. In addition, practicability and compliance
appeared better in this questionnaire version. This could be a
useful tool for future standard QoL evaluation.
6.  Conclusions
In conclusion, our ﬁndings indicate a small deterioration for
global QoL status and large deterioration for cognitive func-
tioning after radiation treatments, as well as worsening of
brain metastasis related symptom items. Our data suggest
that the RPA index, as well as the new GPA index, are valid
prognostic indices. The low survival report reﬂects the poor
outcome of these patients. Further research is necessary to
reﬁne treatment selection for patients with brain metastases,
since it may at least contribute to the stabilization of their QoL
status.Conﬂict  of  interest
Authors declare that they do not have conﬂict of interest with
any ﬁnancial organization.
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